TABLE 2.

Summary of adverse events with an incidence of at least 5% in any group by treatment period

	BIMATOPROST (TP1)/BIMATOPROST (TP2)			VEHICLE (TP1)/BIMATOPROST (TP2)
SYSTEM ORGAN CLASS PREFERRED TERM	0 TO 12 MONTHS (n=96)	0 TO 6 MONTHS (n=96)	6 TO 12 MONTHS (n=89)	0 TO 6 MONTHS (n=33)	6 TO 12 MONTHS (n=32)
Any adverse event	71 (74.0)	55 (57.3)	46 (51.7)	15 (45.5)	17 (53.1)
Eye disorders
Conjunctival hyperemia	16 (16.7)	15 (15.6)	1 (1.1)	1 (3.0)	3 (9.4)
Punctate keratitis	9 (9.4)	8 (8.3)	1 (1.1)	2 (6.1)	1 (3.1)
Eye pruritus	6 (6.3)	5 (5.2)	1 (1.1)	0 (0)	1 (3.1)
Skin and subcutaneous disorders
Skin hyperpigmentation	5 (5.2)	3 (3.1)	2 (2.2)	0 (0)	0 (0)
Infections and infestations
Upper respiratory tract infection	5 (5.2)	2 (2.1)	3 (3.4)	1 (3.0)	3 (9.4)
Sinusitis	5 (5.2)	1 (1.0)	5 (5.6)	0 (0)	0 (0)
Nasopharyngitis	3 (3.1)	0 (0)	3 (3.4)	1 (3.0)	2 (6.3)
Bronchitis	2 (2.1)	2 (2.1)	0 (0)	0 (0)	2 (6.3)
Endocrine disorders
Hypothyroidism	1 (1.0)	1 (1.0)	0 (0)	0 (0)	2 (6.3)

TP=treatment period